Pharma Stocks
-
Assessing Neuren Pharmaceuticals (ASX:NEU) Valuation After Its Latest Annual Earnings Reset
Earnings trigger and why Neuren is on radar Neuren Pharmaceuticals (ASX:NEU) has come into focus after releasing its full year…
Read More » -
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND UAE Thalassemia Approval
Why PYRUKYND’s UAE approval is drawing fresh attention to Agios Pharmaceuticals The recent approval of PYRUKYND (mitapivat) in the United…
Read More » -
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025. Drug pricing agreements…
Read More » -
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Zymeworks Inc. Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30%…
Read More » -
Did EMA’s ENHERTU Validation and Leadership Changes Just Reframe Daiichi Sankyo’s (TSE:4568) Investment Narrative?
In February 2026, Daiichi Sankyo received European Medicines Agency validation to expand the indication of ENHERTU for HER2 positive early…
Read More » -
Amneal Q4 2025 Highlights Shift Toward Higher Value Pharma Segments
Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, highlighting progress across specialty, injectables, biosimilars, and complex generics. The company announced…
Read More » -
Supernus Pharmaceuticals (SUPN) Is Up 7.6% After Record Sales But 2025 Net Loss And Cautious 2026 Outlook
In February 2026, Supernus Pharmaceuticals reported fourth-quarter 2025 revenue of US$211.57 million and record full-year 2025 revenue of US$718.95 million,…
Read More » -
Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.…
Read More » -
Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Revenue And New Oncology Data Release
In late February 2026, Jazz Pharmaceuticals reported fourth‑quarter 2025 revenue of US$1,197.93 million and net income of US$203.45 million, contributing…
Read More » -
Amneal Pharmaceuticals (AMRX) Return To Profit Tests High 60.3x P/E Narrative
Amneal Pharmaceuticals (AMRX) has just posted its FY 2025 numbers, with Q4 revenue of US$814.3 million and basic EPS of…
Read More »